Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Ying Luo Ph.D. | CEO, President, Representative Executive Officer & Chair | 62.63M | -- | 1965 |
| Dr. Kosuke Tashiro | Co-Founder | -- | -- | -- |
| Dr. Cristin Print | Co-Founder | -- | -- | -- |
| Dr. Stephen Charnock-Jones | Co-Founder | -- | -- | -- |
| Toshiya Kitagawa | Executive officer, CFO & Director | -- | -- | 1976 |
| Mr. Sekitani Kazuki | Executive Officer, COO & Director | -- | -- | 1956 |
| Prof. Kan-ichiro Suzuki Ph.D. | VP & Executive Officer | -- | -- | 1954 |
| Kazuhiro Kawauchi | Executive Officer & Chief Business Development Officer | -- | -- | 1962 |
GNI Group Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 843
Description
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573 that is in phase II for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.
Corporate Governance
Upcoming Events
February 14, 2025 at 10:59 AM UTC
GNI Group Ltd. Earnings Date
Recent Events
Recent Events Information Not Available